USFDA grants priority review to Roche’s glofitamab
If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bi-specific antibody approved to treat the most…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Roche
USFDA approves Roche’s lymphoma therapy
The drug, known chemically as mosunetuzumab, can be administered at a hospital’s outpatient centre, unlike some other follicular…
Roche appoints Thomas Schinecker as new Group CEO
The company will propose Severin Schwan as the new Chairman at the Annual General Meeting in 2023
Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Updated data from phase-III Polarix study continue to demonstrate a statistically significant reduction in the risk of disease…
Roche’s Alzheimer’s drug fails to meet goal in long awaited trial
The Swiss drugmaker conducted two identically designed studies, each with about 1,000 participants, who were examined and queried…
FDA accepts supplemental Biologics Licence Application for Roche’s Polivy combination
The acceptance has been given for people with previously untreated diffuse large B-cell lymphoma
EU secures over 50,000 additional doses of Bavarian Nordic’s monkeypox vaccine
The supply deal follows a first contract signed in June, when the EU ordered about 110,000 doses of Bavarian Nordic's vaccine
New data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular…
In the Tenaya and Lucerne studies, more than 60 per cent of Vabysmo patients could be treated every four months at two years. This…
FDA grants priority review to Roche’s Lunsumio for Relapsed or Refractory Follicular Lymphoma
Approval is based on results from the pivotal phase-I/II clinical study of Lunsumio
European Commission approves Roche’s Tecentriq as adjuvant treatment for early-stage NSCLC
The approval marks Tecentriq’s sixth lung cancer indication in Europe